U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07872449) titled 'Risankizumab for Refractory Perianal Fistulizing Crohn's Disease' on Oct. 07.
Brief Summary: Crohn's disease is an inflammatory bowel disease characterized by relapses and remissions, causing lesions throughout the digestive tract and accompanied by diarrhea, abdominal pain, and nutritional disorders. In Japan particularly, the incidence of anal lesions is high, with approximately half of patients developing fistulas or abscesses, significantly impairing quality of life (QOL). For perianal fistulizing Crohn's disease (PFCD), combined treatment with surgical intervention (e.g., seton placement) and medical therapy centered on anti-TN...